Novartis and Meds for Malaria have released positive results from the CALINA study, aimed at developing a malaria treatment for the tiniest babies, a group previously without an evidence-based option. This announcement on World Malaria Day underscores global efforts to combat malaria, including the development of synthetic antibodies by Cristina Donini and Doreen Akiyo Yomoah, and an AI model for automated malaria diagnosis using phone-mounted microscopes.
Synthetic antibodies offer tremendous promise as a tool to prevent malaria and other infectious diseases linked to poverty, say Cristina Donini and Doreen Akiyo Yomoah of @MedsforMalaria. #WorldMalariaDay https://t.co/qmFJHATyUu
Commemorating #WorldMalariaDay2024. Together with @AIR_lab_MUK we're developing an AI model for automated malaria diagnosis on phone-mounted microscopes. This technology has the potential to address personnel shortage in highly endemic, low resourced setting in Uganda. https://t.co/UfBPxUVmjb
WMD: Intensifying the fight against malaria https://t.co/FnP3sYFTuf
Today, @Novartis and @MedsforMalaria announced positive data from the CALINA study exploring a potential medicine formulated for the smallest babies with #malaria, for whom there is currently no evidence-based treatment. https://t.co/yBRdFAtHse https://t.co/FOcEA5IDC4
Novartis and @MedsforMalaria have announced positive data from the trial of a treatment for the tiniest babies with #malaria. This brings us one step closer to ensuring all people can realize their right to an effective malaria treatment. #WorldMalariaDay @EDCTP